RT Journal Article
SR Electronic
T1 Effects of pulmonary rehabilitation on the sensory and affective dimension of dyspnea
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 5183
DO 10.1183/13993003.congress-2020.5183
VO 56
IS suppl 64
A1 Virginie Molinier
A1 Nathalie Fernandes
A1 Pauline Caille
A1 François Alexandre
A1 Nelly Heraud
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/5183.abstract
AB Dyspnea, a major predictor of mortality and quality of life (QoL) in COPD, is essentially explored through its impact (e.g. via the mMRC scale). Many studies highlight two other major components: the sensory (SD) and affective (AD) dimension. Therefore, a multidimensional assessment of dyspnea is recommended in pulmonary rehabilitation (PR). However, studies having concomitantly investigated the SD and AD during PR are scarce. Our aim was thus to study 1) the effects of PR on the SD and AD of dyspnea and 2) the possible predictors of SD and AD response to PR.Seventy COPD patients admitted for a 4-week inpatient PR program were included. In addition to usual data, Multidimensional Dyspnea Profile questionnaire data were collected at the entrance (T1) and at the end (T2) of the PR. Stepwise regression analyses were performed to obtain predictive equations of SD and AD response.In baseline, the mean scores were 38 (± 10) for SD and 22 (± 14) for AD. Post-PR, the SD and AD scores improved significantly: -10.5 (effect size; d=0.81) and -9.5 (d=0.66) respectively. Thirty-seven percent of patients did not improve their scores (n=5 for SD, n=11 for AD and n=10 for both). QoL and AD at T1 predicted AD response (r=0.50, adjusted r2=0.21; standard error of the regression = 9.75).Overall, PR improves the SD and AD of dyspnea with a large and a medium effect size respectively. However, the analysis of individual responses shows that one third of patients does not improve in at least one of the two dimensions. Targeted intervention could be considered to enhance and maintain PR benefits for these patients.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 5183.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).